Filippi, Massimo http://orcid.org/0000-0002-5485-0479
Messina, Roberta
Bartezaghi, Marta
Cetta, Ilaria
Colombo, Bruno
Grazzi, Licia
Martinelli, Daniele
Ornello, Raffaele
Pichiecchio, Anna
Raimondi, Debora
Russo, Antonio
Sacco, Simona
Splendiani, Alessandra
Tassorelli, Cristina
Turrini, Renato
Valsasina, Paola
Rocca, Maria Assunta
Bruno, Federico
Campanella, Angela
Caponnetto, Valeria
Dall’Occhio, Luca
Silvestro, Marcello
Vuotto, Roberto
,
Funding for this research was provided by:
Novartis Pharma
Article History
Received: 8 June 2023
Revised: 12 July 2023
Accepted: 12 July 2023
First Online: 8 August 2023
Declarations
:
: MF is Editor-in-Chief of the <i>Journal of Neurology</i>, Associate Editor of <i>Human Brain Mapping</i>, <i>Neurological Sciences</i>, and <i>Radiology</i>; received compensation for consulting services from Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi; speaking activities from Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA; participation in Advisory Boards for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda; scientific direction of educational events for Biogen, Merck, Roche, Celgene, Bristol-Myers Squibb, Lilly, Novartis, Sanofi-Genzyme; he receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, Italian Ministry of Health, and Fondazione Italiana Sclerosi Multipla. RM reports personal fees from Eli-Lilly, Lunbeck and Bromatech for participating in advisory boards and speaker activities. MB is a Novartis fully employee. IC reports personal fees from Eli-Lilly for speaker activities. BC reports personal fees from Eli-Lilly, Novartis and Teva for speaker activities. LG reports consultancy and advisory fees from AllerganSpA/ABBVie, Electrocore LLC, EliLilly, Novartis AG, EliLilly and Teva. DM has nothing to disclose. RO reports personal fees from Eli Lilly, Novartis, and Teva and received grants from Novartis and Allergan/AbbVie; he is Junior Editor for The Journal of Headache and Pain, Review Editor for Frontiers in Neurology, and Topic Editor for Brain Sciences. AP reports personal fees from Sanofi G-enzyme for participating in advisory boards and speaker activities related to muscle disorders. DR is a Novartis fully employee. AR reports personal fees as speaker or advisor from Allergan-Abbvie, Eli Lilly, Novartis, Roche, Teva. SS reports personal fees as speaker or advisor from Abbott, Allergan-Abbvie, AstraZeneca, Eli Lilly, Lundbeck, Novartis, NovoNordisk, Pfizer, Teva; Research grants from Allergan, Novartis, Uriach; Fees for CME/education: Medscape, Neurodiem Ology Medical Education. SS is president elect European Stroke Organisation, second vice president of the European Headache Federation, specialty chief editor in Headache and Neurogenic Pain for Frontiers in Neurology, associate editor for The Journal of Headache and Pain, and assistant editor for Stroke. AS has nothing to disclose. CT is president of the International Headache Society, Associate Editor of Cephalalgia and of The Journal of Headache and Pain. CT has received received compensation for scientific advice and/or speaking activities for Allergan/Abbvie, Dompé, Eli Lilly, Novartis, Lundbeck, Teva and MDweb. She is PI or co-PI in clinical trials for Allergan/Abbvie, Eli Lilly, Novartis, Lundbeck and Teva. She is PI of competitive research grants funded by the European Commission, Migraine Research Foundation, the Italian Ministry of Health and Fondazione Italiana Sclerosi Multipla. She has received research support from Chiesi, Dompè and Allergan/Abbvie. RT is a Novartis fully employee. PV reports personal fees from Biogen for speaker activities. MAR received consulting fees from Biogen, Bristol Myers Squibb, Eli Lilly, Janssen, Roche; and speaker honoraria from Bayer, Biogen, Bristol Myers Squibb, Bromatech, Celgene, Genzyme, Merck Healthcare Germany, Merck Serono SpA, Novartis, Roche, and Teva. She receives research support from the MS Society of Canada and Fondazione Italiana Sclerosi Multipla. She is Associate Editor for Multiple Sclerosis and Related Disorders.
: This study was approved by institutional review board at all participating sites and all subjects provided written informed consent prior to study participation.